少动鞘氨醇单胞菌临床易感因素分析及药物治疗策略

doi:10.12092/j.issn.1009-2501.2019.08.016

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (8): 944-947.doi: 10.12092/j.issn.1009-2501.2019.08.016

少动鞘氨醇单胞菌临床易感因素分析及药物治疗策略

王焕^1,2，袁晶晶^2,3，屈健²，鲁琼²

¹郑州市第二人民医院药学部，郑州 450000，河南； ²中南大学湘雅二医院药学部，长沙 410011，湖南； ³湖南旺旺医院药学部，长沙 410000，湖南

收稿日期:2019-01-09 修回日期:2019-07-29 出版日期:2019-08-26 发布日期:2019-08-30
通讯作者: 鲁琼，女，硕士，副主任药师，主要从事临床药学工作。 Tel：0731-85292072 E-mail：christy513@163.com
作者简介:王焕，女，本科，药师，主要从事临床药学工作。 Tel：13215998622 E-mail：1521841562@qq.com

Sphingomonas paucimobilis analysis of clinical susceptibility factors and drug treatment strategy

WANG Huan^1,2, YUAN Jingjing ^2,3, QU Jian², LU Qiong ²

¹ Department of Pharmacy, Zhengzhou Second Hospital, Zhengzhou 450000, Henan, China; ²Department of Pharmacy,Second Xiangya Hospital, Central South University, Changsha 410011, Hunan,China;3Department of Pharmacy, Hunan Wantwant Hospital, Changsha 410000, Hunan, China

Received:2019-01-09 Revised:2019-07-29 Online:2019-08-26 Published:2019-08-30

摘要/Abstract

摘要：

目的:了解医院少动鞘氨醇单胞菌易感因素及耐药特点。方法:回顾性分析7例病原学检查提示少动鞘氨醇单胞菌患者的基础疾病、标本来源、抗菌药物用药史和药物敏感性试验。结果:少动鞘氨醇单胞菌对碳青霉烯类及复方新诺明的敏感性较好，对氨基糖苷类及氟喹诺酮类有一定敏感性，对氨曲南和三代头孢敏感性差。结论:少动鞘氨醇单胞菌宿主易感因素除了以往报道的免疫缺陷、肺部感染、广谱抗生素用药史，还可能存在低蛋白血症及乙型病毒性肝炎病史等因素。治疗用药应避免选择氨曲南及三代头孢。

关键词: 少动鞘氨醇单胞菌, 易感因素, 药物选择

Abstract:

AIM: To investigate the susceptibility factors and drug resistance of Sphingomonas paucimobilis in hospital. METHODS: A retrospective analysis of 7 etiology examinations revealed underlying disease, specimen source, antibiotic history, and drug susceptibility testing in patients with Sphingomonas sphaeroides.RESULTS:Sphingomonas sphaeroides had better sensitivity to carbapenems and compound neostigmine, certain sensitivity to aminoglycosides and fluoroquinolones, and poor sensitivity to aztreonam and third generation cephalospores.CONCLUSION: In addition to the previously reported immunodeficiency, pulmonary infection, and broad-spectrum antibiotic history, the predisposing factors of Sphingomonas sphingia may also have factors such as hypoproteinemia and history of hepatitis B virus. Therapeutic medication should avoid the choice of aztreonam and third-generation cephalosporins.

Key words: sphingomonas paucimobilis, susceptibility factor, drug selection

中图分类号:

R378

王焕，袁晶晶，屈健，鲁琼. 少动鞘氨醇单胞菌临床易感因素分析及药物治疗策略[J]. 中国临床药理学与治疗学, 2019, 24(8): 944-947.

WANG Huan, YUAN Jingjing, QU Jian, LU Qiong. Sphingomonas paucimobilis analysis of clinical susceptibility factors and drug treatment strategy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 944-947.

参考文献

［1］Kuo I, Lu PL, Lin WR, et al. Sphingomonas paucimobilis bacteraemia and septic arthritis in a diabetic patient presenting with septic pulmonary emboli［J］.J Med Microbiol, 2009, 58(9):1259-1263.
［2］Bolen RD, Palavecino E, Gomadam A, et al. Sphingomonas paucimobilis meningitis and ventriculitis in an immunocompromised host［J］. J Neurol Sci, 2015, 359(1/2):18-20.
［3］El Beaino M,Fares J,Malek A,et al.Sphingomonas paucimobilis-related bone and soft-tissue infections: A systematic review［J］.Int J Infect Dis，2018，77:68-73.
［4］Kawahara K,Kuraishi H,Zhringer U.Chemical structure and function of glycosphingolipids of Sphingomonas spp and their distribution among members of the alpha-4 subclass of Proteobacteria［J］.J Ind Microbiol Biotechnol，1999,23(4/5):408-413.
［5］Pinyakong O, Habe H, Omori T.The unique aromatic catabolic genes in sphingomonads degrading polycyclic aromatic hydrocarbons (PAHs)［J］.J Gen Appl Microbiol，2003，49(1):1-19.
［6］Bayram N, Devrim I, Apa H, et al. Sphingomonas paucimobilis infections in children: 24 case reports［J］. Mediterr J Hematol Infect Dis，2013，5(1):e2013040.
［7］Benevides GN, Hein N, Lo DS,et al.Otomastoiditis caused by Sphingomonas paucimobilis: case report and literature review［J］.Autops Case Rep，2014，4(3):13-20.
［8］华春珍, 娄国强, Richard M. 少动鞘氨醇单胞菌及其感染的临床特点和治疗［J］.中华传染病杂志, 2012, 30(12):751-754.
［9］Hardjo Lugito NP, Cucunawangsih, Kurniawan A.A lethal case of sphingomonas paucimobilis bacteremia in an immunocompromised patient［J］. Case Rep Infect Dis，2016, 2016:3294639.
［10］Lin JN, Lai CH, Chen YH , et al. Sphingomonas paucimobilis Bacteremia in Humans: 16 Case Reports and a Literature Review［J］. J Microbiol Immunol Infect, 2010, 43(1):35-42.
［11］来汉江, 杨莉俊, 周鸿亮, 等.116例少动鞘氨醇单胞菌的医院感染及耐药特点［J］.中华医院感染学杂志, 2010, 20(4):581-583.
［12］Vincent JL,Dubois MJ,NaVickis RJ,et al.Hypoalbuminemia in acute illness: is there a rationale for intervention?A meta-analysis of cohort studies and controlled trials［J］.Ann Surg，2003，237（3）:319-334.
［13］Li F, Yuan MZ, Wang L, et al.Characteristics and prognosis of pulmonary infection in patients with neurologic disease and hypoproteinemia［J］. Expert Rev Anti Infect Ther, 2015, 13(4):521-526.
［14］殷稼雯,王进科,殷国庆.HBV感染免疫学应答的新进展和新观点［J］.中国肝脏病杂志(电子版),2016,8(3):34-37.
［15］Sullivan A, Edlund C, Nord CE.Effect of antimicrobial agents on the ecological balance of human microflora［J］.Lancet Infect Dis，2012，18(2):249-253.
［16］Kuo I, Lu PL, Lin WR, et al. Sphingomonas paucimobilis bacteraemia and septic arthritis in a diabetic patient presenting with septic pulmonary emboli［J］.J Med Microbiol，2009, 58(9):1259-1263.
［17］Corkill JE, Hart CA, Mclennan AG, et al. Characterization of a beta-lactamase produced by Pseudomonas paucimobilis［J］. J Gen Microbiol, 1991, 137(6):1425-1429.
［18］Leekha S, Terrell CL, Edson RS.General principles of antimicrobial therapy［J］. Mayo Clin Proc，2011，86(2):156-167.

[1]	乔红亮, 丁宁, 邓凯红, 刘彬彬, 董传江, 陈晓波, 邹黎黎. 耐甲氧西林金黄色葡萄球菌感染新型控制策略研究新进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 676-687.
[2]	方青，欧阳冬生. 氧化三甲胺与炎症性疾病[J]. 中国临床药理学与治疗学, 2019, 24(3): 318-326.
[3]	李乃静, 李岩, 潘作东, 何平, 李胜岐. 生物被膜肺炎克雷伯杆菌AmpC酶、超广谱β-内酰胺酶的检测[J]. 中国临床药理学与治疗学, 2008, 13(4): 384-387.

少动鞘氨醇单胞菌临床易感因素分析及药物治疗策略

Sphingomonas paucimobilis analysis of clinical susceptibility factors and drug treatment strategy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价